Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Boehringer Ingelheim Biopharmaceuticals has signed a manufacturing deal to provide process development and clinical phase I supply to Apexigen's monoclonal antibody.
Subscribe to our email newsletter
As a part of the contract, Boehringer will offer cell line development along with high expression BI-HEX system, full process and method development and scale-up for APX005, an anti-CD40 agonist.
Apexigen will also receive early stage clinical supply simultaneously with fill and finish development for the humanized monoclonal antibody that demonstrated effective anti-cancer activities in preclinical research.
Boehringer Ingelheim biopharmaceuticals senior vice president Simon Sturge said, "We are confident that our cutting edge production process technologies will advance Apexigen’s robust clinical program."
Boehringer Ingelheim Biopharma Contract Manufacturing rebranded to Boehringer Ingelheim BioXcellence offers contract development and manufacturing services including complete production technology.